L. Harrison

Type 1 Diabetes Treatment Beyond Insulin

I. Lingvay, P. Mora, L. Harrison, 2013, Journal of Investigative Medicine.

Effect of Adding Liraglutide vs Placebo to a High-Dose lnsulin Regimen in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

B. Adams-Huet, I. Lingvay, L. Harrison, 2016, JAMA internal medicine.

Intensive Therapy in Newly Diagnosed Type 2 Diabetes

P. Raskin, B. Adams-Huet, I. Lingvay, 2014, Journal of Investigative Medicine.

Response to Comment on: Harrison et al. β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. Diabetes Care 2012;35:1406–1412

P. Raskin, I. Lingvay, L. Harrison, 2012, Diabetes Care.

The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high‐dose insulin

B. Adams-Huet, I. Lingvay, L. Harrison, 2017, Diabetes, obesity & metabolism.

Dual-parameter model for prediction of type I diabetes mellitus.

H. Chase, M. Redondo, G. Eisenbarth, 1998, Proceedings of the Association of American Physicians.

β-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy

P. Raskin, B. Adams-Huet, I. Lingvay, 2012, Diabetes Care.

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.

Diane M. Miller, Natalia E. Shilkina, M. C. Cantero, 2018, Lancet.

Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin.

Laurentiu M. Pop, R. Lenkinski, I. Pedrosa, 2016, The Journal of clinical endocrinology and metabolism.